10% at Grace Therapeutics, Inc. Buys $136,178 in Stock

Opaleye Management Inc., who serves as 10% at Grace Therapeutics, Inc. (GRCE), purchased 71,065 shares of the company's stock, according to a disclosure filed with the U.S. Securities and Exchange Commission.

The transaction was executed at a price of $1.92 per share, for a total value of approximately $136,178.

Insider transactions of this kind are publicly disclosed through Form 4 filings with the SEC, which must generally be submitted within two business days of the trade date.

Insider buying is sometimes viewed by investors as a signal of confidence in a company's prospects, though a single transaction does not necessarily indicate a broader trend.